Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zim LaboratoriesNSE:ZIMLAB +2.00%78 Equity-to-Asset is 0.55 as of Mar. 2026, which is 10% above its 10-year median of 0.50. GuruFocus rates NSE:ZIMLAB with a GF Score™ of 78/100 and a GF Value™ of ₹102.66 (Modestly Overvalued). The stock has 8 warning signs investors should review. Among 1,006 Drug Manufacturers companies, Zim Laboratories ranks worse than 58.55% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Zim Laboratories's Total Stockholders Equity for the quarter that ended in Mar. 2026 was ₹2,962 Mil. Zim Laboratories's Total Assets for the quarter that ended in Mar. 2026 was ₹5,394 Mil.
Therefore, Zim Laboratories's Equity to Asset Ratio for the quarter that ended in Mar. 2026 was 0.55.
The historical rank and industry rank for Zim Laboratories's Equity-to-Asset or its related term are showing as below:
NSE:ZIMLAB'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.46 Med: 0.5 Max: 0.59
Current: 0.55
During the past 12 years, the highest Equity to Asset Ratio of Zim Laboratories was 0.59. The lowest was 0.46. And the median was 0.50.
NSE:ZIMLAB's Equity-to-Asset is ranked worse than 58.55% of 1006
companies
in the Drug Manufacturers industry
Industry Median: 0.61
vs NSE:ZIMLAB: 0.55
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Zim Laboratories Equity-to-Asset Related Terms
Zim Laboratories Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Zim Laboratories's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:ZIMLAB vs ZTS, UTHR: Equity-to-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Zim Laboratories's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zim Laboratories Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Zim Laboratories's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Zim Laboratories's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Zim Laboratories's Equity to Asset Ratio for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zim Laboratories (NSE:ZIMLAB) has a Equity-to-Asset of 0.55 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Zim Laboratories and its competitors. This is 10% above median its historical median of 0.50. Over the past decade, Zim Laboratories' Equity-to-Asset has ranged from 0.46 to 0.59. According to the industry distribution chart, Zim Laboratories ranks #589 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 58.5%.
Is Zim Laboratories' Equity-to-Asset too high?
Zim Laboratories' current Equity-to-Asset of 0.55 is 10% above median its 10-year median of 0.50. Over the past 10 years, this metric has ranged from a low of 0.46 to a high of 0.59. The Drug Manufacturers industry median Equity-to-Asset is 0.61. Zim Laboratories' value of 0.55 is 9.8% below this industry median. Based on the distribution chart, Zim Laboratories ranks #589 out of 1006 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Zim Laboratories has a GF Score™ of 78/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Zim Laboratories' Equity-to-Asset compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Zim Laboratories ranks #589 out of 1006 companies for Equity-to-Asset. This places Zim Laboratories in the lower half of its industry. The industry median Equity-to-Asset is 0.61. Zim Laboratories' value of 0.55 is 9.8% below this benchmark. Historically, Zim Laboratories' own Equity-to-Asset has ranged from 0.46 to 0.59 over the past decade. While the company's 10-year median is 0.50 vs. the industry median of 0.61, Zim Laboratories has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.61, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zim Laboratories's current Equity-to-Asset of 0.55 is 9.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Zim Laboratories and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zim Laboratories's current Equity-to-Asset is 0.55, which is 10% above median its own 10-year median of 0.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zim Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Zim Laboratories (NSE:ZIMLAB) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹102.66, compared to a current price of ₹118.85 — trading 15.8% above its estimated fair value. The current Equity-to-Asset is 0.55, which is 10% above median its 10-year median of 0.50 and 9.8% below the Drug Manufacturers industry median of 0.61. Zim Laboratories' overall GF Score™ is 78/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Zim Laboratories (NSE:ZIMLAB), the current Equity-to-Asset is 0.55 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zim Laboratories (NSE:ZIMLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Zim Laboratories stock appears to be overvalued.
The current stock price of ₹118.85 is trading 15.8% above its estimated GF Value™ of ₹102.66.
GuruFocus considers Zim Laboratories to be Modestly Overvalued.
Key valuation signals for NSE:ZIMLAB:
Equity-to-Asset: 0.55 (10% above median its 10-year median of 0.50)
GF Value™: ₹102.66 vs. price of ₹118.85 (15.8% above fair value)
Industry Position: 9.8% below the Drug Manufacturers median (#589 of 1006)
No single metric tells the full story. See the NSE:ZIMLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zim Laboratories Ltd is engaged in the manufacturing of formulation drugs and pre formulation ingredients in India and marketing and selling these within and outside India. It is engaged in manufacturing &wholesale of pharmaceutical products, market research and research & development activities. The Group is mainly engaged in the business of pharmaceuticals. It has presence in India and Outside India. The company generates majority of revenue from India. Its products are Oral Thin Films, Pre-formulations Intermediates, Finished Formulations.
78GF Score
Get the complete analysis for NSE:ZIMLAB
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ZIMLAB has been successfully added to your 
